
CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (II), or a pharmaceutically acceptable salt or stereoisomer thereof:



Formula (II),

wherein:

Ring A is phenyl or heteroaryl;

each R^A is independently hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R^{Aa};

or two R^A on the same atom are taken together to form an oxo;

each R^{Aa} is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, -$C(=O)C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

or two R^{Aa} on the same atom are taken together to form an oxo;

n is 0-4;

R^1 and R^2 are independently hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

or R^1 and R^2 are taken together to form an oxo;

or R^1 and R^2 are taken together to form a cycloalkyl or heterocycloalkyl; wherein the cycloalkyl and heterocycloalkyl is optionally substituted with deuterium, halogen, -CN, -OH, -OCH_3, -NH_2, -$NHCH_3$, -

$N(CH_3)_2$, -C(=O)CH_3, -C(=O)OH, -C(=O)OCH_3, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

X is -$C(R^3)_2$-, -NR^4-, -O-, or -S-;

each R^3 are independently hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

or two R^3 are taken together to form an oxo;

R^4 is hydrogen, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

R^5 is hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

R^6 is hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

R^7 is hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, or heterocycloalkyl;

Ring B is heterocycloalkyl or heteroaryl;

each R^B is independently hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -OC(=O)R^a, -OC(=O)OR^b, -OC(=O)NR^cR^d, -SH, -SR^a, -S(=O)R^a, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R^{Ba};

or two R^B on the same atom are taken together to form an oxo;

each R^{Ba} is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -OC(=O)R^a, -OC(=O)OR^b, -OC(=O)NR^cR^d, -SH, -SR^a, -S(=O)R^a, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -C(=O)R^a, -C(=O)C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, -C(=O)C(=O)NR^cR^d, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

or two R^{Ba} on the same atom are taken together to form an oxo;

m is 0-4;

Ring C is 5-membered heteroaryl;

each R^C is independently hydrogen, deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -$S(=O)(=NR^b)R^a$, -$SiR^cR^dOR^b$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (C_1-C_6alkyl)cycloalkyl, (C_1-C_6alkyl)heterocycloalkyl, (C_1-C_6alkyl)aryl, or (C_1-C_6alkyl)heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R^{Ca};

each R^{Ca} is independently deuterium, halogen, -CN, -NO_2, -OH, -OR^a, -$OC(=O)R^a$, -$OC(=O)OR^b$, -$OC(=O)NR^cR^d$, -SH, -SR^a, -$S(=O)R^a$, -$S(=O)_2R^a$, -$S(=O)_2NR^cR^d$, -NR^cR^d, -$NR^bC(=O)NR^cR^d$, -$NR^bC(=O)R^a$, -$NR^bC(=O)OR^b$, -$NR^bS(=O)_2R^a$, -$C(=O)R^a$, -$C(=O)C(=O)R^a$, -$C(=O)OR^b$, -$C(=O)NR^cR^d$, -$C(=O)C(=O)NR^cR^d$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

or two R^{Ca} on the same atom are taken together to form an oxo;

p is 0-4;


each R^a is independently C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OCH_3, -$S(=O)CH_3$, -$S(=O)_2CH_3$, -$S(=O)_2NH_2$, -$S(=O)_2NHCH_3$, -$S(=O)_2N(CH_3)_2$, -NH_2, -$NHCH_3$, -$N(CH_3)_2$, -$C(=O)CH_3$, -C(=O)OH, -$C(=O)OCH_3$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

each R^b is independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, -OCH_3, -$S(=O)CH_3$, -$S(=O)_2CH_3$, -$S(=O)_2NH_2$, -$S(=O)_2NHCH_3$, -$S(=O)_2N(CH_3)_2$, -NH_2, -$NHCH_3$, -$N(CH_3)_2$, -$C(=O)CH_3$, -C(=O)OH, -$C(=O)OCH_3$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl; and

each R^c and R^d are independently hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, C_1-C_6heteroalkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6alkyl(cycloalkyl), C_1-C_6alkyl(heterocycloalkyl), C_1-C_6alkyl(aryl), or C_1-C_6alkyl(heteroaryl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo,

deuterium, halogen, -CN, -OH, $-OCH_3$, $-S(=O)CH_3$, $-S(=O)_2CH_3$, $-S(=O)_2NH_2$, $-S(=O)_2NHCH_3$, $-S(=O)_2N(CH_3)_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-C(=O)CH_3$, -C(=O)OH, $-C(=O)OCH_3$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

or R^c and R^d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, -CN, -OH, $-OCH_3$, $-S(=O)CH_3$, $-S(=O)_2CH_3$, $-S(=O)_2NH_2$, $-S(=O)_2NHCH_3$, $-S(=O)_2N(CH_3)_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-C(=O)CH_3$, -C(=O)OH, $-C(=O)OCH_3$, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6deuteroalkyl, C_1-C_6hydroxyalkyl, C_1-C_6aminoalkyl, or C_1-C_6heteroalkyl;

provided that the compound is not 











.













2. The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is pyridyl.
3. The compound of claims 1 or 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R^A is independently halogen.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein n is 1 or 2.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^1 and R^2 are hydrogen or deuterium.
6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is -O-.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^5 is hydrogen, deuterium, halogen, -CN, or C_1-C_6alkyl.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^6 is hydrogen, deuterium, halogen, -CN, or C_1-C_6alkyl.
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^7 is hydrogen, deuterium, halogen, -CN, or C_1-C_6alkyl.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring B is pyridinyl.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R^B is independently halogen or C_1-C_6alkyl.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein m is 1 or 2.
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring C is thiazolyl, pyrazolyl, imidazolyl, oxazolyl, thiadiazole, or triazolyl.













14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R^C is independently C_1-C_6hydroxyalkyl.















15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein p is 1 or 2.

16. A compound seleted from:
















,

,

,

,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,
















,

,

,

.

,

,

,

,

,

,

,

,












































































, 
,




, 
,


, 
,




, 
,




, 
,




, 
,




, 
,



, 
,




, 
,




, 
,
















, 
,


, 
,


, 
,









, 
,


, 
,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

, and

;

or a pharmaceutically acceptable salt or stereoisomer thereof.

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-16, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient.

18. Use of a therapeutically effective amount of a compound of any one of claim 1-16, or a pharmaceutically acceptable salt or stereoisomer thereof, in the preparation of a medicament for treating a condition selected from the group consisting of an autoimmune disorder, a chronic inflammatory disorder, an acute inflammatory disorder, an auto-inflammatory disorder, a fibrotic disorder, a metabolic disorder, a neoplastic disorder, and a cardiovascular or a cerebrovascular disorder in a subject in need thereof.

19. Use of a compound of any one of claims 1-16, or a pharmaceutically acceptable salt or stereoisomer thereof, in the preparation of a medicament for treating a p38 MAP kinase-mediated disease in a subject in need thereof.

20. Use of a compound of any one of claims 1-16, or a pharmaceutically acceptable salt or stereoisomer thereof, in the preparation of a medicament for treating a MK2-mediated disease in a subject in need thereof.